234 related articles for article (PubMed ID: 23267123)
1. Anticancer efficacy of the metabolic blocker 3-bromopyruvate: specific molecular targeting.
Ganapathy-Kanniappan S; Kunjithapatham R; Geschwind JF
Anticancer Res; 2013 Jan; 33(1):13-20. PubMed ID: 23267123
[TBL] [Abstract][Full Text] [Related]
2. A perillyl alcohol-conjugated analog of 3-bromopyruvate without cellular uptake dependency on monocarboxylate transporter 1 and with activity in 3-BP-resistant tumor cells.
Chen TC; Yu J; Nouri Nigjeh E; Wang W; Myint PT; Zandi E; Hofman FM; Schönthal AH
Cancer Lett; 2017 Aug; 400():161-174. PubMed ID: 28450161
[TBL] [Abstract][Full Text] [Related]
3. Glutamine deprivation enhances antitumor activity of 3-bromopyruvate through the stabilization of monocarboxylate transporter-1.
Cardaci S; Rizza S; Filomeni G; Bernardini R; Bertocchi F; Mattei M; Paci M; Rotilio G; Ciriolo MR
Cancer Res; 2012 Sep; 72(17):4526-36. PubMed ID: 22773663
[TBL] [Abstract][Full Text] [Related]
4. 3-bromopyruvate inhibits glycolysis, depletes cellular glutathione, and compromises the viability of cultured primary rat astrocytes.
Ehrke E; Arend C; Dringen R
J Neurosci Res; 2015 Jul; 93(7):1138-46. PubMed ID: 25196479
[TBL] [Abstract][Full Text] [Related]
5. 3-bromopyruvate: a new targeted antiglycolytic agent and a promise for cancer therapy.
Ganapathy-Kanniappan S; Vali M; Kunjithapatham R; Buijs M; Syed LH; Rao PP; Ota S; Kwak BK; Loffroy R; Geschwind JF
Curr Pharm Biotechnol; 2010 Aug; 11(5):510-7. PubMed ID: 20420565
[TBL] [Abstract][Full Text] [Related]
6. Deregulation of glycolysis in cancer: glyceraldehyde-3-phosphate dehydrogenase as a therapeutic target.
Krasnov GS; Dmitriev AA; Snezhkina AV; Kudryavtseva AV
Expert Opin Ther Targets; 2013 Jun; 17(6):681-93. PubMed ID: 23445303
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of energy-producing pathways of HepG2 cells by 3-bromopyruvate.
Pereira da Silva AP; El-Bacha T; Kyaw N; dos Santos RS; da-Silva WS; Almeida FC; Da Poian AT; Galina A
Biochem J; 2009 Feb; 417(3):717-26. PubMed ID: 18945211
[TBL] [Abstract][Full Text] [Related]
8. Targets of 3-bromopyruvate, a new, energy depleting, anticancer agent.
Dell'Antone P
Med Chem; 2009 Nov; 5(6):491-6. PubMed ID: 19534685
[TBL] [Abstract][Full Text] [Related]
9. Deprive to kill: glutamine closes the gate to anticancer monocarboxylic drugs.
Cardaci S; Ciriolo MR
Autophagy; 2012 Dec; 8(12):1830-2. PubMed ID: 22932475
[TBL] [Abstract][Full Text] [Related]
10. 3-Bromopyruvate as a potent anticancer therapy in honor and memory of the late Professor André Goffeau.
Ko YH; Niedźwiecka K; Casal M; Pedersen PL; Ułaszewski S
Yeast; 2019 Apr; 36(4):211-221. PubMed ID: 30462852
[TBL] [Abstract][Full Text] [Related]
11. Butyrate activates the monocarboxylate transporter MCT4 expression in breast cancer cells and enhances the antitumor activity of 3-bromopyruvate.
Queirós O; Preto A; Pacheco A; Pinheiro C; Azevedo-Silva J; Moreira R; Pedro M; Ko YH; Pedersen PL; Baltazar F; Casal M
J Bioenerg Biomembr; 2012 Feb; 44(1):141-53. PubMed ID: 22350013
[TBL] [Abstract][Full Text] [Related]
12. Glycolytic enzyme inhibitors affect pancreatic cancer survival by modulating its signaling and energetics.
Bhardwaj V; Rizvi N; Lai MB; Lai JC; Bhushan A
Anticancer Res; 2010 Mar; 30(3):743-9. PubMed ID: 20392992
[TBL] [Abstract][Full Text] [Related]
13. Transport by SLC5A8 with subsequent inhibition of histone deacetylase 1 (HDAC1) and HDAC3 underlies the antitumor activity of 3-bromopyruvate.
Thangaraju M; Karunakaran SK; Itagaki S; Gopal E; Elangovan S; Prasad PD; Ganapathy V
Cancer; 2009 Oct; 115(20):4655-66. PubMed ID: 19637353
[TBL] [Abstract][Full Text] [Related]
14. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is pyruvylated during 3-bromopyruvate mediated cancer cell death.
Ganapathy-Kanniappan S; Geschwind JF; Kunjithapatham R; Buijs M; Vossen JA; Tchernyshyov I; Cole RN; Syed LH; Rao PP; Ota S; Vali M
Anticancer Res; 2009 Dec; 29(12):4909-18. PubMed ID: 20044597
[TBL] [Abstract][Full Text] [Related]
15. Over-expression of GAPDH in human colorectal carcinoma as a preferred target of 3-bromopyruvate propyl ester.
Tang Z; Yuan S; Hu Y; Zhang H; Wu W; Zeng Z; Yang J; Yun J; Xu R; Huang P
J Bioenerg Biomembr; 2012 Feb; 44(1):117-25. PubMed ID: 22350014
[TBL] [Abstract][Full Text] [Related]
16. Monocarboxylate transporters as targets and mediators in cancer therapy response.
Baltazar F; Pinheiro C; Morais-Santos F; Azevedo-Silva J; Queirós O; Preto A; Casal M
Histol Histopathol; 2014 Dec; 29(12):1511-24. PubMed ID: 24921258
[TBL] [Abstract][Full Text] [Related]
17. Glucose catabolism in African trypanosomes. Evidence that the terminal step is catalyzed by a pyruvate transporter capable of facilitating uptake of toxic analogs.
Barnard JP; Reynafarje B; Pedersen PL
J Biol Chem; 1993 Feb; 268(5):3654-61. PubMed ID: 8429041
[TBL] [Abstract][Full Text] [Related]
18. Warburg effect increases steady-state ROS condition in cancer cells through decreasing their antioxidant capacities (anticancer effects of 3-bromopyruvate through antagonizing Warburg effect).
El Sayed SM; Mahmoud AA; El Sawy SA; Abdelaal EA; Fouad AM; Yousif RS; Hashim MS; Hemdan SB; Kadry ZM; Abdelmoaty MA; Gabr AG; Omran FM; Nabo MM; Ahmed NS
Med Hypotheses; 2013 Nov; 81(5):866-70. PubMed ID: 24071366
[TBL] [Abstract][Full Text] [Related]
19. Killing multiple myeloma cells with the small molecule 3-bromopyruvate: implications for therapy.
Majkowska-Skrobek G; Augustyniak D; Lis P; Bartkowiak A; Gonchar M; Ko YH; Pedersen PL; Goffeau A; Ułaszewski S
Anticancer Drugs; 2014 Jul; 25(6):673-82. PubMed ID: 24557015
[TBL] [Abstract][Full Text] [Related]
20. Discovery of novel glyceraldehyde-3-phosphate dehydrogenase inhibitor via docking-based virtual screening.
Li T; Tan X; Yang R; Miao Y; Zhang M; Xi Y; Guo R; Zheng M; Li B
Bioorg Chem; 2020 Mar; 96():103620. PubMed ID: 32028064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
